Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Total Current Liabilities
All obligations due within one year.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 53.4% from a year ago
Total current liabilities stood at $1.62M at the end of Q1 FY2026, up 53.4% from a year earlier and up 25.0% from the prior quarter.
Context
- Total current liabilities amounted to 0.8% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +53.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.3M USD
- Year-over-year change
- +78.7%
- 1-year CAGR
- +78.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.3M | +78.7% |
| FY2024 | 2024-12-31 | 727.32K | — |
Total Current Liabilities vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's Mar 2026 total current liabilities of $1.62M is the 4th highest of the 10 companies compared; the peer median is $823.3K.
- Its year-over-year change of +53.4% is the 7th highest of 10, against a peer median of +90.8%.
- Total current liabilities amounts to 0.8% of total assets for OACC, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | Mar 2026 | $8M | +827.0% | — | 2.6% |
| Mar 2026 | $3.39M | +4032.1% | — | 1.3% | |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | Mar 2026 | $3.17M | +2788.9% | — | 1.4% |
OACCOaktree Acquisition Corp. III Life Sciences | Mar 2026 | $1.62M | +53.4% | — | 0.8% |
| Mar 2026 | $1.39M | +86.5% | — | 0.5% | |
| Mar 2026 | $823.3K | +90.8% | — | 0.3% | |
| Mar 2026 | $340.65K | +138.1% | -57.9% | 0.1% | |
| Mar 2026 | $138.74K | +9.2% | -84.0% | 0.1% | |
| Mar 2026 | $71.6K | -68.0% | — | 0.0% | |
COPLCopley Acquisition Corp | Mar 2026 | $61.16K | -88.6% | — | 0.3% |
| Peer median (excluding OACC) | $823.3K | +90.8% | -70.9% | 0.3% | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 1.36M | 1.43M |
| Short-term Investments | 0 | 0 |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 0 | 0 |
| Total Current Assets | 1.56M | 1.55M |
| Property, Plant & Equipment (Net) | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 193.58M | 201.56M |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 113.28K | 0 |
| Total Non-current Assets | 193.69M | 201.56M |
| Total Assets | 195.25M | 203.11M |
| Account Payables | 0 | 0 |
| Short-term Debt | 11.82K | 11.82K |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 0 |
| Other Current Liabilities | 179.98K | 1.29M |
| Total Current Liabilities | 727.32K | 1.3M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 7.02M | 7.02M |
| Total Non-current Liabilities | 7.02M | 7.02M |
| Total Liabilities | 7.75M | 8.32M |
| Common Stock | 193.58M | 201.56M |
| Retained Earnings | (6.08M) | (6.77M) |
| Accumulated OCI | 0 | 0 |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | 187.5M | 194.79M |
| Total Debt | 11.82K | 11.82K |
| Net Debt | (1.35M) | (1.42M) |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.